The following is a summary of “Circular RNA_0003489 reflects unfavorable treatment response and shortened survival in newly diagnosed multiple myeloma patients who receive bortezomib-based induction ...

aDepartment of Hematology/Oncology, Comprehensive Cancer Center (CCC Munich), LMU University Hospital Munich, 81377 Munich, Germany bDepartment of Hematology, Oncology, and Cancer Immunology (CCM), ...

Stormont Vail Health has hired a board-certified internist specializing in hematology and oncology.Dr. Alec Britt was ...

The $21 million new building, at 5490 Cobbler Way, replaces the cancer practice’s longtime western suburban facility on the ...

Sickle cell carriers are at a slightly increased risk of blood clots, but the overall risk is still low, a study found.

An NIH-supported clinical trial of pomalidomide in treating hereditary hemorrhagic telangiectasia stopped early due to ...

Physicians in the US, Germany, and France show gaps in their knowledge of the treatment of of refractory/relapsed chronic ...

While infections pose a risk for morbidity and mortality among patients with MDS, more needs to be studied about the topic, ...

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious ...

September is Blood Cancer Awareness Month and today we're at AstraZeneca's campus in Gaithersburg where they are co-hosting a ...

A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder.

She works in the newly opened Camillus Cancer Center.